Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial

Circulation

Volumn 99, Issue 15, 1999, Pages 1951-1958

  Lincoff, A Michael ^a   Tcheng, James E ^a   Califf, Robert M ^b   Kereiakes, Dean J ^c   Kelly, Thomas A ^d   Timmis, Gerald C ^e   Kleiman, Neal S ^f   Booth, Joan E ^a   Balog, Craig ^a   Cabot, Catherine F ^g   Anderson, Keaven M ^g   Weisman, Harlan F ^g   Topol, Eric J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c CHRIST HOSPITAL   (United States)

^d MOSES H CONE MEMORIAL HOSPITAL   (United States)

^e WILLIAM BEAUMONT HOSPITAL   (United States)

^f HOUSTON METHODIST HOSPITAL   (United States)

^g CENTOCOR INC   (United States)

Author keywords

Angioplasty; Glycoproteins; Platelets; Receptors; Revascularization; Thrombosis

Indexed keywords

ABCIXIMAB; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT;

EID: 0033586696     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.15.1951     Document Type: Article

References (14)

1. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
2. EPILOG Investigators. Platelet glycoprotein IIb/IIIa blockade with abciximab with low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
3. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. 1997;349:1429-1435.
4. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 1998;352:87-92.
5. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelel inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation. 1998;97:1680-1688.
6. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994;90:1757-1764.
7. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM, for the EPIC Investigator Group. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA. 1997;278:479-484.
8. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol. 1991;17:621-626.
9. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary intervention. Circulation. 1996;94:1528-1536.
10. Kugelmass AD, Cohen CJ, Moscucci M, Piana RN, Senerchia C, Kuntz RE, Baim DS. Elevation in creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol. 1994;74:748-754.
11. Harrington RA, Lincoff AM, Califf RM, Holmes DR, Berdan LG, O'Hanesian MA, Keeler GP, Garratt KN, Ohman EM, Mark DB, Jacobs AK, Topol EJ, for the CAVEAT investigators. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the coronary angioplasty versus excisional atherectomy trial (CAVEAT). J Am Coll Cardiol. 1995;25:1693-1699.
12. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA. 1997;277:461-466.
13. Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, Mahaffey KW, Teirstein P, Heinsimer J, Topol EJ, for the IMPACT-II Investigators. Post-intervention cardiac enzyme elevations: prognostic significance in IMPACT II. J Am Coll Cardiol. 1996;27:83A. Abstract.
14. Redwood SR, Popma JJ, Kent KK, Pichard AD, Satler LF, Mintz GS, Hong MK, Bucher TA, Merritt AJ, Leon MB. Predictors of late mortality following ablative new-device angioplasty in native coronary arteries. J Am Coll Cardiol. 1996;27:167A. Abstract.